Abstract
Background Data on risk factors for COVID-19-associated hospitalisation and mortality in high HIV prevalence settings are limited.
Methods Using existing syndromic surveillance programs for influenza-like-illness and severe respiratory illness at sentinel sites in South Africa, we identified factors associated with COVID-19 hospitalisation and mortality.
Results From April 2020 through March 2022, SARS-CoV-2 was detected in 24.0% (660/2746) of outpatient and 32.5% (2282/7025) of inpatient cases. Factors associated with COVID-19-associated hospitalisation included: older age (25-44 [adjusted odds ratio (aOR) 1.8, 95% confidence interval (CI) 1.1-2.9], 45-64 [aOR 6.8, 95%CI 4.2-11.0] and ≥65 years [aOR 26.6, 95%CI 14.4-49.1] vs 15-24 years); black race (aOR 3.3, 95%CI 2.2-5.0); obesity (aOR 2.3, 95%CI 1.4-3.9); asthma (aOR 3.5, 95%CI 1.4-8.9); diabetes mellitus (aOR 5.3, 95%CI 3.1-9.3); HIV with CD4 ≥200/mm3 (aOR 1.5, 95%CI 1.1-2.2) and CD4<200/mm3 (aOR 10.5, 95%CI 5.1-21.6) or tuberculosis (aOR 12.8, 95%CI 2.8-58.5). Infection with Beta (aOR 0.5, 95%CI 0.3-0.7) vs Delta variant and being fully vaccinated (aOR 0.1, 95%CI 0.1-0.3) were less associated with COVID-19 hospitalisation.
In-hospital mortality was increased in older age (45-64 years [aOR 2.2, 95%CI 1.6-3.2] and ≥65 years [aOR 4.0, 95%CI 2.8-5.8] vs 25-44 years) and male sex (aOR1.3, 95%CI 1.0-1.6) and was lower in Omicron -infected (aOR 0.3, 95%CI 0.2-0.6) vs Delta-infected individuals.
Conclusion Active syndromic surveillance encompassing clinical, laboratory and genomic data identified setting-specific risk factors associated with COVID-19 severity that will inform prioritization of COVID-19 vaccine distribution. Elderly, people with tuberculosis or people living with HIV, especially severely immunosuppressed should be prioritised for vaccination.
Summary of article’s viewpoint Compared to the Delta variant, the Omicron variant was associated with reduced risk of mortality and Beta associated with decreased risk of hospitalisation. Active syndromic surveillance combining clinical, laboratory and genomic data can be used to describe the epidemic timing, epidemiological characteristics of cases, early detection of variants of concern and how these impact disease severity and outcomes; and presents a viable surveillance approach in settings where national surveillance is not possible.
Competing Interest Statement
SM received an investigational grant from Sanofi Pasteur unrelated to this research. NW and AvG received funding from Sanofi, and the Bill and Melinda Gates Foundation. CC has received funding from the Wellcome Trust and US CDC related to this work and PATH, South African Medical Research Council, Sanofi, and the Bill and Melinda Gates Foundation unrelated to this work. MdP has received funding from the Bill and Melinda Gates foundation and the National Research Foundation, South Africa, unrelated to this work. JM has received grant funds from Pfizer, unrelated to this work.
Funding Statement
The study was funded by the Wellcome Trust [grant number 221003/Z/20/Z] in collaboration with the Foreign, Commonwealth and Development Office, United Kingdom; the U.S. Centers for Disease Control and Prevention [co-operative agreement number: Award # NU51IP000930 and FAIN# U01IP001048];funds through the CDC under the terms of a subcontract with the African Field Epidemiology Network (AFENET) AF-NICD-001/2021, the South African Medical Research Council (SAMRC, project number 96838); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978, as well as the National Institute for Communicable Diseases, a division of the National Health Laboratory Service, South Africa. The funding agencies had no role in the development of the study protocol, data collection, analysis and interpretation, writing of the report, or decision to submit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ILI and SRI protocols were approved by the University of Witwatersrand Human Research Ethics Committee (HREC), reference M180832 and M140824, respectively.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos